Source: World Health Organization Intellectual property plays an important role both for the researching pharmaceutical industry, which relies heavily on intellectual property to protect its products, and for generic companies, which produce copies of existing medicines once patent protection expires. … Continue reading
Hepatitis C patients in Malaysia urgently need access to affordable Sofosbuvir. Help them by signing this petition to the Health Minister of Malaysia in the run-up to the International Harm Reduction Conference in Kuala Lumpur.
MUMBAI, SEPT 15: Source: The Hindu California-based Gilead is set to stir the pot as it forges India-based alliances on its Hepatitis C drug sofosbuvir. Multi-company agreements on the drug are expected to be announced later today. Never before has … Continue reading
Gilead, local generic players in talks to bring hepatitis C drug into India PT JYOTHI DATTA Source:Hindu Business Line Price to be pegged lower than the current standard of care, estimated at $2,500 for six months MUMBAI, FEBRUARY 3: California-based … Continue reading
Health groups call for wide public consultation Johannesburg, 9 September – The Treatment Action Campaign (TAC), Doctors Without Borders (MSF) and SECTION27 welcome the announcement that the Department of Trade and Industry (DTI) has called for public comment on the … Continue reading
Posted in BRICS, Compulsory Licensing, Generics, IP Rights, Post-grant opposition, Pre-grant opposition, Pricing, Right to Health, TRIPS, WHO, WTO
Tagged Department of Trade and Industry (DTI), draft IP policy, Treatment Action Campaign (TAC)